# Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis

> **NCT03132623** · PHASE4 · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Acute Bronchitis

## Interventions

- **DRUG:** andrographolide sulfonate
- **DRUG:** andrographolide sulfonate simulation

## Key facts

- **NCT ID:** NCT03132623
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-01
- **Primary completion:** 2017-12-30
- **Final completion:** 2018-06-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03132623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03132623, "Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03132623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*